Urdu Version of Arthritis Impact Measurement Scales 2 Short Form:Reliability and Validity Study
Launched by RIPHAH INTERNATIONAL UNIVERSITY · Feb 4, 2022
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
The main aim of this study is to translate and culturally adapt AIMS2 SF into Urdu language and to investigate the reliability and validity of AIMS2 SF in Osteoarthritis patients among Urdu speaking Pakistani population.
The study will be completed in 5 steps such as translation ,synthesis ,back translation ,expert committee review and pre testing. The study will be a cross sectional survey .The result of the study helps to know the validity and reliability of AIMS2 SF in Urdu Version to check the quality of life .The reliability of the scale will be checked through internal consistency an...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male and Female Patient age 18 years or older.
- • 2. Diagnosed with OA of the knee , hip and hand .
- • 3. Patients diagnosed according to ACR criteria. 4 - X-RAY scored according to Kellgren and Lawrence Classification.
- Exclusion Criteria:
- • 1 - Radiograph not older than 6 months . 2- Age less than 18 are excluded from this study.
About Riphah International University
Riphah International University is a leading educational institution based in Pakistan, dedicated to advancing healthcare and medical research through innovative clinical trials. With a commitment to excellence in research and education, Riphah emphasizes ethical standards and scientific integrity in its clinical studies. The university collaborates with various stakeholders, including healthcare professionals and industry partners, to enhance patient outcomes and contribute to the global body of medical knowledge. Through its robust research programs, Riphah International University aims to foster a culture of inquiry and improve healthcare delivery both locally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Faisalabad, Punjab, Pakistan
Patients applied
Trial Officials
Muhammad Kashif
Study Chair
Riphah International University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials